Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma : Pancreas

Secondary Logo

Journal Logo

Advanced Search
Original Articles

Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma

Sukeda, Aoi MD∗,†; Nakamura, Yuka∗; Nishida, Yasunori MD, PhD‡,§,∥; Kojima, Motohiro MD, PhD‡,§; Gotohda, Naoto MD, PhD∥; Akimoto, Tetsuo MD, PhD†,¶,#; Ochiai, Atsushi MD, PhD∗,‡

Author Information

From the ∗Division of Biomarker Discovery, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa-shi, Chiba

†Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo

‡Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East

§Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center

Departments of ∥Hepatobiliary and Pancreatic Surgery

¶Radiation Oncology, National Cancer Center Hospital East

#Division of Radiation Oncology and Particle Therapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa-shi, Chiba, Japan.

Received for publication January 14, 2019; accepted June 24, 2019.

Address correspondence to: Atsushi Ochiai, MD, PhD, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577 Japan (e-mail: [email protected]).

The present investigation received the support of the National Cancer Center Research and Development Fund (29-A-5).

The authors declare no conflict of interest.

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.pancreasjournal.com).

Pancreas 48(8):p 1102-1110, September 2019. | DOI: 10.1097/MPA.0000000000001369

Abstract

Objectives 

Because lactate is believed to support tumor growth, monocarboxylate transporters (MCTs), which transport lactate, have been investigated in multiple tumors. However, the significance of MCTs in pancreatic cancer is unclear.

Methods 

A retrospective survey was conducted on 240 patients who underwent surgical resection for pancreatic ductal adenocarcinoma without preoperative treatment. The expression of MCT1, MCT2, MCT3, MCT4, and the glucose transporter 1 (GLUT1) was assessed in tumor cells and cancer-associated fibroblasts (CAFs) by tissue microarrays and immunohistochemistry. The impact of their expression on patient outcome and clinicopathological characteristics was also analyzed.

Results 

In tumor cells, MCT1, MCT2, MCT3, MCT4, and GLUT1 were detected in 52 (22%), 31 (13%), 149 (62%), 204 (85%), and 235 (98%) cases, respectively. In CAFs, MCT2, MCT4, and GLUT1 were detected in 9 (3.8%), 178 (74%), and 36 (15%) cases, respectively. In tumor cells, MCT1 expression was associated with extended overall and progression-free survival and decreased nodal metastasis. Conversely, MCT4 expression in CAFs was associated with shortened survival.

Conclusions 

In tumor cells, MCT1 expression is associated with better prognosis and reduced nodal metastasis in pancreatic cancer, contrary to findings of past in vitro studies. Conversely, MCT4 expression in CAFs is indicative of worse prognosis.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid